SIRPA and neoplasm: The usage of a soluble recombinant fusion protein encoding the N-terminal CD47 binding domain of human SIRPα was proven effective as anti-tumor therapy for selected hematopoietic malignancies and several solid tumors, including glioblastoma (reviewed in [160]).